Antibody-drug conjugates in breast cancer: Marching from HER2-overexpression into HER2-low-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Antibody-drug conjugates in breast cancer: Marching from HER2-overexpression into HER2-low

Published:2023-01 Issue:1 Volume:1878 Page:188849
ISSN:0304-419X
Container-title:Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
language:en
Short-container-title:Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

Author:

Fan Pinchao,Xu Kun

Publisher

Elsevier BV

Subject

Cancer Research,Genetics,Oncology

Reference99 articles.

1. Cancer Statistics, 2022. vol. 72;Siegel,2022

2. Breast Cancer. vol. 389;Harbeck,2017

3. Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Guidelines in 2022: Stratification and Classification;Li,2022

4. Breast Cancer Treatment: A Review. vol. 321;Waks,2019

5. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. vol. 35;Jiang,2019

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models;Journal of Translational Medicine;2024-08-14

2. Surface-Available HER2 Levels Alone Are Not Indicative of Cell Response to HER2-Targeted Antibody–Drug Conjugate Therapies;Pharmaceutics;2024-06-02

3. Discrimination between HER2-overexpressing, -low-expressing, and -zero-expressing statuses in breast cancer using multiparametric MRI-based radiomics;European Radiology;2024-02-16

4. Prognostic Impact of HER2-Low and HER2-Zero in Resectable Breast Cancer with Different Hormone Receptor Status: A Landmark Analysis of Real-World Data from the National Cancer Center of China;Targeted Oncology;2024-01

5. Clinicopathological features and prognostic analysis of HER2 low and fibrotic focus in HER2-negative breast cancer;Breast Cancer Research and Treatment;2023-10-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3